share_log

Merck & Co | 4: Statement of changes in beneficial ownership of securities-10% Owner Merck & Co., Inc.

SEC announcement ·  Mar 12 03:32
Summary by Futu AI
Merck & Co., Inc. has engaged in a significant transaction involving the purchase of Harpoon Therapeutics, Inc. (HARP) common stock. On March 11, 2024, Merck & Co. acquired 21,397,205 shares of Harpoon Therapeutics at a price of $23.00 per share. Following this transaction, Merck & Co. holds a total of 1,000 shares in Harpoon Therapeutics. The transaction is currently in progress and reflects a direct ownership type, as indicated in the acquisition log.
Merck & Co., Inc. has engaged in a significant transaction involving the purchase of Harpoon Therapeutics, Inc. (HARP) common stock. On March 11, 2024, Merck & Co. acquired 21,397,205 shares of Harpoon Therapeutics at a price of $23.00 per share. Following this transaction, Merck & Co. holds a total of 1,000 shares in Harpoon Therapeutics. The transaction is currently in progress and reflects a direct ownership type, as indicated in the acquisition log.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.